Completed PHASE2 INTERVENTIONAL 2-arm NCT03181503

Safety and Efficacy of Nemolizumab in PN

A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)

Sponsor: Galderma R&D

Interventions CD14152 Dose A CD14152 placebo

Updated 8 times since 2017 Last updated: Feb 7, 2020 Started: Oct 2, 2017 Primary completion: Sep 26, 2018 Completion: Sep 26, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prurigo Nodularis and is currently completed. Galderma R&D leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Oct 2019 — Mar 2020 [monthly]

Completed PHASE2
Mar 2019 — Oct 2019 [monthly]

Completed PHASE2

Status: Not Yet Recruiting → Completed
Jun 2017 — Mar 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galderma R&D

Data source: Galderma R&D

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bonn, Germany , Brest, France , Frankfurt, Germany , Graz, Austria , Lodz, Poland , Lübeck, Germany , Mainz, Germany , München, Germany , Münster, Germany and 5 more locations